INM · CIK 0001728328 · FY2025 live · 2025-06-30
InMed Pharmaceuticals Inc.
View as
Model
Classic Z
FY2025
−5.61
Zone
Distress
Prior
—
Market DD
—
1y PD
—
Meridian Rank
32.45
0–100 · Classic Z tape · not a PD
Book standing
15
Year change
—
Market PD
—
O-score
79
Events on this name
Same published rows as Today. Not a live recompute.
Market PD unavailable
watch · 41
−5.61
Z″ −13.31
Score −5.61 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.711.2 × = 0.85X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−7.521.4 × = −10.53X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
0.003.3 × = 0.00X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
6.260.6 × = 3.76X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.321 × = 0.32
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
InMed Pharmaceuticals Inc. is on classic Z at −5.61 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 27th percentile in Healthcare.
- DRIODistressDarioHealth Corp.−5.60
- CRVSDistressCorvus Pharmaceuticals, Inc.−5.58
- ABVCDistressABVC BIOPHARMA, INC.−5.58
- EQDistressEquillium, Inc.−5.67
- TVRDDistressTvardi Therapeutics, Inc.−5.68
- REVBDistressREVELATION BIOSCIENCES, INC.−5.69
- BFRIDistressBiofrontera Inc.−5.51
- FBIODistressFortress Biotech, Inc.−5.72
KPI widgets
Current assets
$13M
Total assets
$16M
Current liabilities
$2M
Total liabilities
$2M
Working capital
$11M
Retained earnings
−$117M
EBIT
$0
Total sales
$5M
Book equity
$13M
Accession 0001213900-25-090210. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-06-30). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 13 Sept 2026.